@article{oai:repo.qst.go.jp:00046511,
 author = {Karasawa, Kumiko and Matsumoto, Fumihiko and Ito, Shin and Oba, Shinichi and Furuya, Tomohisa and Hirowatari, Hisako and Izawa, Hiromi and Ito, Kana and Sasai, Keisuke and 唐澤 久美子 and 笹井 啓資},
 issue = {9},
 journal = {Anticancer Research},
 month = {Sep},
 note = {Aim: To evaluate the value of hyperfractionated radiotherapy with concurrent use of low-dose docetaxel in locally-advanced head and neck squamous cell cancer (HNSCC). Patients and Methods: Patients eligible for this study had confirmed diagnosis of HNSCC stages II (>10 cm3) to IVB. Radiotherapy was delivered twice daily at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m2) was administered weekly during radiotherapy. Results: From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n=3). Major grade 3 acute toxicities included mucositis (n=43) and treatment-related pain (n=20). The median follow-up period for surviving patients was 43 months. The 5-year local control rate and overall survival rate were 62.6% and 61.6%, respectively. Conclusion: This modality is a valuable treatment option for the management of locally-advanced HNSCC.},
 pages = {4013--4018},
 title = {Hyperfractionated Radiotherapy with Concurrent Docetaxel for Advanced Head and Neck Cancer: A Phase II Study},
 volume = {32},
 year = {2012}
}